Adjuvant Therapy for Melanoma Prolongs RFS
- PMID: 29657137
- DOI: 10.1158/2159-8290.CD-NB2018-047
Adjuvant Therapy for Melanoma Prolongs RFS
Abstract
The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival rate of 75.4%, compared with 61% for patients who received a placebo.
©2018 American Association for Cancer Research.
Comment on
-
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15. N Engl J Med. 2018. PMID: 29658430 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical